

**Fact Sheet**

**Glioblastoma Multiforme: References**

**Author: Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy**

Text

Description automatically generatedA picture containing drawing

Description automatically generated

**References:**

1. Brain and Spinal Cord Tumors in Adults. Accessed December 28, 2020. https://www.cancer.org/cancer/brain-spinal-cord-tumors-adults.html
2. Brain Cancer Research - National Cancer Institute. Published April 30, 2015. Accessed December 28, 2020. https://www.cancer.gov/types/brain/research
3. Cancer of the Brain and Other Nervous System - Cancer Stat Facts. SEER. Accessed December 7, 2020. https://seer.cancer.gov/statfacts/html/brain.html
4. Glioblastoma Multiforme – Symptoms, Diagnosis and Treatment Options. Accessed December 7, 2020. https://www.aans.org/
5. Laws ER, Thapar K. Brain tumors. *CA Cancer J Clin*. 1993;43(5):263-271. doi:https://doi.org/10.3322/canjclin.43.5.263
6. Cancer Management Chapter 23: Primary and metastatic brain tumors. Cancer Network. Accessed December 29, 2020. https://www.cancernetwork.com/view/cancer-management-chapter-23-primary-and-metastatic-brain-tumors
7. Brain Tumors—Patient Version - National Cancer Institute. Accessed December 28, 2020. https://www.cancer.gov/types/brain
8. Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version - National Cancer Institute. Published May 11, 2020. Accessed December 28, 2020. https://www.cancer.gov/types/brain/patient/adult-brain-treatment-pdq
9. Zhu P, Zhu J-J. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. *Chin Clin Oncol*. 2017;6(4):41. doi:10.21037/cco.2017.06.29
10. Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2018;24(2):266-275. doi:10.1158/1078-0432.CCR-17-1117
11. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. *JAMA*. 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718
12. Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. *JAMA*. 2015;314(23):2535-2543. doi:10.1001/jama.2015.16669
13. Davis ME. Glioblastoma: Overview of Disease and Treatment. *Clin J Oncol Nurs*. 2016;20(5):S2-S8. doi:10.1188/16.CJON.S1.2-8
14. Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review. *Curr Med Chem*. 2017;24(27):3002-3009. doi:10.2174/0929867324666170516123206
15. Karnofsky D. The clinical evaluation of chemotherapeutic agents in cancer. undefined. Published 1949. Accessed December 28, 2020. /paper/The-clinical-evaluation-of-chemotherapeutic-agents-Karnofsky/ee9f2644a4ef6a7b18f787b5d46a32b131791d66
16. Tang V, Rathbone M, Park Dorsay J, Jiang S, Harvey D. Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival. *J Neurol*. 2008;255(6):820-827. doi:10.1007/s00415-008-0695-z
17. Temodar Side Effects: Common, Severe, Long Term. Drugs.com. Accessed December 28, 2020. https://www.drugs.com/sfx/temodar-side-effects.html
18. Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids compromise survival in

A Special Interest Group of

**Contact us:**

ANPT

Phone: 952.646.2038

info@neuropt.org

www.neuropt.org

a component of

**Produced by**

Text

Description automatically generatedA picture containing drawing

Description automatically generated

glioblastoma. *Brain J Neurol*. 2016;139(Pt 5):1458-1471. doi:10.1093/brain/aww046

1. Vecht C, Royer-Perron L, Houillier C, Huberfeld G. Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management. *Curr Pharm Des*. 2017;23(42):6464-6487. doi:10.2174/1381612823666171027130003
2. Gately L, McLachlan SA, Dowling A, Philip J. Life beyond a diagnosis of glioblastoma: a systematic review of the literature. *J Cancer Surviv Res Pract*. 2017;11(4):447-452. doi:10.1007/s11764-017-0602-7
3. Lee J, Chaloner Winton Hall R. The Impact of Gliomas on Cognition and Capacity. *J Am Acad Psychiatry Law*. 2019;47(3):350-359. doi:10.29158/JAAPL.003841-19
4. Hemminger LE, Pittman CA, Korones DN, et al. Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care. *Neuro-Oncol Pract*. 2017;4(3):182-188. doi:10.1093/nop/npw022
5. CAR T Cells: Engineering Immune Cells to Treat Cancer - National Cancer Institute. Published December 6, 2013. Accessed December 29, 2020. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
6. Batich KA, Reap EA, Archer GE, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2017;23(8):1898-1909. doi:10.1158/1078-0432.CCR-16-2057
7. Pembrolizumab - National Cancer Institute. Published September 18, 2014. Accessed December 29, 2020. https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab
8. Nassiri F, Chakravarthy A, Feng S, et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. *Nat Med*. 2020;26(7):1044-1047. doi:10.1038/s41591-020-0932-2
9. Glioblastoma—Unraveling the Threads to Make Progress - National Cancer Institute. Published August 3, 2017. Accessed December 29, 2020. https://www.cancer.gov/news-events/cancer-currents-blog/2017/glioblastoma-research-making-progress
10. Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). *Neuro-Oncol*. 2016;18(Suppl 2):ii26-ii36. doi:10.1093/neuonc/nov270
11. Study Reveals Sex Differences in Glioblastoma - National Cancer Institute. Published January 30, 2019. Accessed December 29, 2020. https://www.cancer.gov/news-events/cancer-currents-blog/2019/glioblastoma-treatment-response-differs-by-sex
12. Kfoury N, Sun T, Yu K, et al. Cooperative p16 and p21 action protects female astrocytes from transformation. *Acta Neuropathol Commun*. 2018;6. doi:10.1186/s40478-018-0513-5
13. Kfoury N, Sun T, Yu K, et al. Cooperative p16 and p21 action protects female astrocytes from transformation. *Acta Neuropathol Commun*. 2018;6. doi:10.1186/s40478-018-0513-5
14. 32. Study Reveals Sex Differences in Glioblastoma - National Cancer Institute. Published January 30, 2019. Accessed December 28, 2020. https://www.cancer.gov/news-events/cancer-currents-blog/2019/glioblastoma-treatment-response-differs-by-sex
15. 33. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. *Acta Neuropathol (Berl)*. 2015;129(6):829-848. doi:10.1007/s00401-015-1432-1

a component of

**Produced by**

**a Special Interest Group of**

**Glioblastoma Multiforme: References**